Elvitegravir, cobicistat, emtricitabine, and tenofovir and St. John's wort interaction
Elvitegravir, cobicistat, emtricitabine, and tenofovir and St. John's wort: the Elvitegravir, cobicistat, emtricitabine, and tenofovir prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Elvitegravir, cobicistat, emtricitabine, and tenofovir (Genvoya) label · effective 2025-02-03
John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly…
John's wort (Hypericum perforatum) ↓ elvitegravir ↓ cobicistat ↓ TAF Coadministration is contraindicated due to potential for loss of therapeutic effect and development of resistance .
Curated guidance for St. John's wort
St. John's wort can lower blood levels of some HIV medicines enough to cause treatment failure.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.